Hansoh Pharmaceutical Group Company Limited (HK:3692) has released an update.
Hansoh Pharmaceutical Group Company Limited reported a robust financial performance for the first half of 2024, with a 44.2% surge in revenue to approximately RMB 6,506 million, and a striking 111.5% jump in profit at RMB 2,726 million, compared to the same period in 2023. The growth was significantly propelled by their innovative drugs and collaborative products, which now constitute 77.4% of the company’s total revenue. Additionally, the company has declared an interim dividend of HK$20.10 cents per share, underscoring its commitment to delivering shareholder value.
For further insights into HK:3692 stock, check out TipRanks’ Stock Analysis page.
